Adverum
2 known investors
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform. Its therapies aim to transform retinal cells into biofactories that continually produce anti-VEGF protein, reducing the need for frequent eye injections.
Investors Β· 2
Frequently asked questions
- What does Adverum do?
- Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform. Its therapies aim to transform retinal cells into biofactories that continually produce anti-VEGF protein, reducing the need for frequent eye injections.
- Who are Adverum's investors?
- Adverum's investors include Avoro Capital Advisors, Frazier Life Sciences.